Elan Pharmaceuticals, Inc. (Ireland)
Impact in
- Physiology top 5%
- Alzheimer's disease research and treatments
- Neurology top 10%
- Parkinson's Disease Mechanisms and Treatments
- Neuroinflammation and Neurodegeneration Mechanisms
Papers in
-
- Drug Solubulity and Delivery Systems 32
- Advanced Drug Delivery Systems 16
- Physiology 100
- Alzheimer's disease research and treatments 92
- Top scholars
- Dale SchenkHenry Michael ArrighiRon BrookmeyerKathryn Ziegler‐GrahamElizabeth M. JohnsonDora GamesCharles S. DavisPeter A. Seubert
- Journals
- Alzheimer s & Dementia (22 papers)Bioorganic & Medicinal Chemistry Letters (17 papers)Journal of Neuroscience (11 papers)Advances in experimental medicine and biology (11 papers)Journal of Biological Chemistry (10 papers)
- Partner nations
- IrelandUnited StatesUnited Kingdom
In The Last Decade
Elan Pharmaceuticals, Inc. (Ireland)
290 papers receiving 36.8k citations
Peers
Comparison fields: 5 of 195
- Physiology 17.5k
- Neurology 3.8k
- Pharmaceutical Science 1.8k
- Neurology 2k
- Psychiatry and Mental health 3.7k
Countries citing scholars working at Elan Pharmaceuticals, Inc. (Ireland)
This map shows the geographic impact of research produced by authors working at Elan Pharmaceuticals, Inc. (Ireland). It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by papers produced at Elan Pharmaceuticals, Inc. (Ireland) with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elan Pharmaceuticals, Inc. (Ireland) more than expected).
Fields of papers published by authors at Elan Pharmaceuticals, Inc. (Ireland)
This network shows the impact of papers affiliated with Elan Pharmaceuticals, Inc. (Ireland) at the time of their publication. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers affiliated with Elan Pharmaceuticals, Inc. (Ireland) at the time of their publication.
About Elan Pharmaceuticals, Inc. (Ireland)
In recent decades, authors affiliated with Elan Pharmaceuticals, Inc. (Ireland) have published 291 papers, which have received a total of 36.8k indexed citations . Scholars at this organization have produced 45 papers in Pharmaceutical Science, 100 papers in Physiology, 30 papers in Neurology, 8 papers in Immunology and Allergy and 28 papers in Psychiatry and Mental health on the topics of Alzheimer's disease research and treatments (92 papers), Drug Solubulity and Delivery Systems (32 papers), Dementia and Cognitive Impairment Research (25 papers), Parkinson's Disease Mechanisms and Treatments (20 papers), Advanced Drug Delivery Systems (16 papers), Pharmaceutical studies and practices (10 papers), Multiple Sclerosis Research Studies (9 papers) and Botulinum Toxin and Related Neurological Disorders (8 papers). Their work is cited by papers focused on Physiology (17.5k citations), Neurology (3.8k citations), Pharmaceutical Science (1.8k citations), Neurology (2k citations) and Psychiatry and Mental health (3.7k citations). Authors at Elan Pharmaceuticals, Inc. (Ireland) collaborate with scholars in Ireland, United States and United Kingdom and have published in prestigious journals including Alzheimer s & Dementia, Bioorganic & Medicinal Chemistry Letters, Journal of Neuroscience, Advances in experimental medicine and biology and Journal of Biological Chemistry. Some of Elan Pharmaceuticals, Inc. (Ireland)'s most productive authors include Dale Schenk, Henry Michael Arrighi, Ron Brookmeyer, Kathryn Ziegler‐Graham, Elizabeth M. Johnson, Dora Games, Charles S. Davis, Peter A. Seubert, Dennis J. Selkoe and Gary G. Liversidge.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.